H&T Presspart

H&T Presspart is a manufacturer of drug delivery devices and components with more than 50 years’ experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market.

UK OFFICE
H&T Presspart Manufacturing Ltd
Whitebirk Industrial Estate
Blackburn
Lancashire
BB1 5RF
United Kingdom

Phone / Contact

T: +44 1254 582 233
E: [email protected]

Connect

H&T Presspart is a manufacturer of drug delivery devices and components with more than 50 years’ experience and enjoys a worldwide reputation for competence, quality and innovation in the pharmaceutical market. H&T Presspart’s Technology Center supports its customers’ new product developments and strategic initiatives. H&T Presspart has four European manufacturing sites in Germany, Spain, Switzerland and the UK and also has sales representation in China, India, the US and Uruguay.

H&T Presspart is a development and manufacturing company specialising in respiratory drug delivery devices and components. Its products include metered-dose inhaler (MDI) counters, actuators and canisters; the PowdAir Plus dry-powder inhaler; the connected eMDI. Its manufacturing services including deep-drawing of MDI canisters, injection moulding, a surface treatment for MDI canisters, and device assembly. H&T Presspart components are used in 85% of the world’s MDIs.

The company was founded in 1970 and acquired by the private German holding company, Heitkamp and Thumann Group (H&T), in 2002.

Articles by H&T Presspart

Ana Isabel Gutierrez

VYTAL – ONE STEP INTO THE FUTURE OF CONTAINER-CLOSURE SYSTEMS

Ana Isabel Gutierrez looks at advancements in sterile and aseptic filling methods in the pharmaceutical industry, introducing H&T Presspart's Vytal® snap-fit container-closure system, which is designed to meet the growing regulatory demands of the pharmaceutical industry.

DRIVING SUSTAINABLE DRUG DELIVERY DEVICES WITH CONTINUOUS IMPROVEMENT PROCESSES

Marc Severin discusses the H&T Excellence programme and how it has been expanded to include methods and training to help H&T Presspart identify environmental impact at a product group level and take co-ordinated action to reduce carbon emissions across the organisation.

Dr Mirjam Kobler

DEVELOPMENT APPROACH FOR A HIGH-PERFORMANCE CAPSULE-BASED DPI

Mirjam Kobler, Ameet Sule and Sunita Sule look at the factors affecting the performance of dry powder inhalers and discuss the company’s development of high-performance prototypes.

Jacqueline Green

PLASMA TECHNOLOGY – THE FUTURE OF RESPIRATORY DEVICES

Jacqueline Green discusses how H&T Presspart’s plasma treatment process can provide a future-proof and sustainable solution for some of the issues associated with suspension formulations in the respiratory device industry.

CUTTING CARBON IMPACT: CREATING A SUSTAINABLE pMDI COMPONENT SUPPLY CHAIN

Wim Kehoe and Ameet Sule discuss H&T Presspart’s approach to sustainability, and the developments that are helping to reduce the carbon footprint of pMDIs.

Dr Benjamin Jung

THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A NETWORK PERSPECTIVE

Benjamin Jung uses a network theory approach to look at the ongoing issue of adherence when it comes to the treatment of asthma and COPD, and the players involved in overcoming it.

INDUSTRIALISATION

GAS PLASMA PROCESSING: A LONG-TERM SOLUTION FOR RESPIRATORY DEVICES

Ameet Sule, Head of H&T Presspart’s Inhalation Product Technology Centre (IPCT), discusses the new challenges arising in metered dose inhaler design since the change from CFC to HFA propellants.

Dr Benjamin Jung

THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A STEPWISE DEVELOPMENT

Benjamin Jung outlines possible scenarios for the likely steps in the development and adoption of connected devices in the field of asthma and COPD care.

Dr Anselm Ebert

A SIMPLE AFFORDABLE DPI: MEETING THE NEEDS OF EMERGING MARKETS

Anselm Ebert, João Ventura Fernandes, Ameet Sule and Sunita Sule discuss the rising need for respiratory medication in the developing world. They go on to highlight the novel challenges presented by these new markets and explain how a new DPI, PowdAir Plus™, meets those challenges, offering a solution to the increase in chronic respiratory conditions across the globe.

Dr Benjamin Jung

EMBEDDED CONNECTED METERED DOSE INHALERS MEETING REQUIREMENTS FOR MASS ADOPTION

Benjamin Jung and Dana Shears describe the role connected devices can play in the treatment of asthma and COPD, discuss the requirements for mass adoption, and introduce H&T Presspart's inhaler, the eMDI, which has connectivity fully embedded.

DOSE COUNTERS & INDICATORS – MEETING A REAL PATIENT NEED

Inga Meyerand Kyle Wilson explain how their dose counter-enabled inhaler development work has led to the production of a system that accurately indicates the end of life of a device.

IMPROVING DRUG STABILITY & DRUG DELIVERY BY MODIFICATION OF MDI CANISTER SURFACES

Richard Turner explains how, in recent years, a number of surface coatings have been developed that can be applied to MDIs canisters and valve components, to protect the contents from deposition and degradation.

Top